Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

catumaxomab 1Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) × Clear all
NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Neovii Biotech

Phase 2/3 Completed
258 enrolled
BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡